At 7.8% CAGR, Middle East & Africa Fill Finish Manufacturing Market is Projected to be Worth US$ 953.58 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa fill finish manufacturing market was valued at US$ 522.33 million in 2022 and is expected to reach US$ 953.58 million by 2030, registering a CAGR of 7.8% from 2022 to 2030. Growing adoption of prefilled syringes for parenteral administration and significant government initiatives is the critical factors attributed to the Middle East & Africa fill finish manufacturing market expansion.

Parenteral administration is one of the most prominent routes chosen to stimulate immediate immune response and ensure the complete bioavailability of pharmaceutical products. A steady rise in the development and market availability of parenteral drugs has propelled the demand for advanced, cost-effective drug delivery devices that promise ease of administration. The benefits of prefilled syringes over traditional delivery systems include easy administration, improved safety, accurate dosing, and reduced contamination risks. Among drug delivery devices, prefilled syringes represent one of the fastest-growing primary packaging formats, which are designed for dose administration. In the past ten years, there has been an evident increase in the development of parenteral drugs (especially with the introduction of several classes of biologics), which has resulted in approximately three-fold increase in the consumption of prefilled syringes. The sustained preference for the prefilled syringes is attributed to the safety and ease of use of these products. Recent variants are designed with provisions to reduce errors in dosing, risk of occlusions, leakage of fluids (i.e., extravasation), and inflammation of veins (phlebitis). Owing to the benefits mentioned above, several injectable drugs-Humira, Enbrel, Avastin, PREVNAR 13, ALPROLIX, and Benefix, among others-diluents and other products requiring parenteral administration are packaged in prefilled syringes.

The loading of sterile drugs into prefilled syringes is considered one of the most crucial steps in the pharmaceutical production process. Proper fill-finish operations are necessarily carried out under aseptic conditions to maintain pharmacological efficacy and quality and to ensure the safety of end users. The prefilled syringe filling is a complex operation as it requires extremely close monitoring of both the syringe fill volume and the headspace between the liquid filled in the syringe and the bottom of the plunger. In addition, the rise in complexity of small molecule APIs and the increasing diversity of biological drugs contribute to the demand for advanced aseptic fill finish operations.

Companies, including small enterprises and large businesses, outsource their respective fill finish operations to contract service providers. Per the 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, manufacturers of biological have been observed to outsource more than 30% of their fill finish operations. With the rise in the demand for prefilled syringes and the growing complexity of fill finish processes, outsourcing these operations is likely to increase in the future. Over 100 companies across the globe are providing fill finish services for prefilled syringe manufacturers. To cater to the growing demand of pharmaceutical products, service providers are actively investing in expanding their existing infrastructure and capabilities; they have also expanded their clientele through service agreements over the past few years. As injectables account for ~55% of drug candidates in the global R&D pipeline, the businesses of prefilled syringe manufacturers and associated service providers are also growing. Due to the emergence of the COVID-19 crisis, vaccine development initiatives have increased across the globe, which significantly boosted the demand for prefilled syringes. Thus, the rising adoption of prefilled syringes for parenteral administration drives the fill finish manufacturing market.

On the contrary, growing competition in biopharmaceutical contract manufacturing industry hurdles the growth of Middle East & Africa fill finish manufacturing market.

Based on product, the Middle East & Africa fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held 56.6% share of Middle East & Africa fill finish manufacturing market in 2022, amassing US$ 295.81 million. It is projected to garner US$ 554.14 million by 2030 to expand at 8.2% CAGR during 2022-2030. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.

In terms of modality, the Middle East & Africa fill finish manufacturing market is categorized into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held 32.2% share of Middle East & Africa fill finish manufacturing market in 2022, amassing US$ 167.97 million. It is projected to garner US$ 317.55 million by 2030 to expand at 8.3% CAGR during 2022-2030.

By end user, the Middle East & Africa fill finish manufacturing market is segmented into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held 50.6% share of Middle East & Africa fill finish manufacturing market in 2022, amassing US$ 263.62 million. It is projected to garner US$ 489.63 million by 2030 to expand at 8.0% CAGR during 2022-2030.

Based on country, the Middle East & Africa fill finish manufacturing market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that South Africa captured 34.6% share of Middle East & Africa fill finish manufacturing market in 2022. It was assessed at US$ 180.52 million in 2022 and is likely to hit US$ 341.09 million by 2030, exhibiting a CAGR of 8.3% during 2022-2030.

Key players operating in the Middle East & Africa fill finish manufacturing market are Becton Dickinson and Co, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Middle East & Africa NV, Schott AG, SGD SA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc, among others.

• In September 2022, BD announced the launch of BD Effivax Glass Prefillable Syringe. In collaboration with leading pharmaceutical companies, the prefillable syringe was designed to meet the complex and evolving needs of vaccine manufacturing. The launch of prefillable syringe strategically would support growth and would create needed efficiencies in end-to-end production.
  
  
• In October 2023, Dara Pharma will be present at CPhI, sharing the Booth 2C29 with its partner ARaymond, and will exhibit a filling and closing machine for vials in nest and RayDyLyo caps, model NFL/2-RDL.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com